

Afuresertib (hydrochloride)

Catalog No: tcsc3385



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

1047645-82-8

Formula:

$C_{18}H_{18}Cl_3FN_4OS$

Pathway:

PI3K/Akt/mTOR

Target:

Akt

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 52 mg/mL (112.12 mM)

Alternative Names:

GSK 2110183B

Observed Molecular Weight:


463.78

Product Description

Afuresertib hydrochloride is a potent and ATP-competitive specific **Akt** inhibitor.

IC50 & Target: Akt^[1]

In Vitro: Afuresertib exhibits favorable tumor-suppressive effects on malignant pleural mesothelioma (MPM) cells. Afuresertib significantly increases caspase-3 and caspase-7 activities and apoptotic cell number among ACC-MESO-4 and MSTO-211H cells. Afuresertib strongly arrests the cell cycle in the G₁ phase. Western blotting analysis shows that Afuresertib increases the expression of p21^{WAF1/CIP1} and decreases the phosphorylation of Akt substrates, including GSK-3 β and FOXO family proteins. Afuresertib-induced p21 expression promotes G₁ phase arrest by inducing FOXO activity. Afuresertib significantly enhances cisplatin-induced cytotoxicity. Afuresertib modulates the expression *E2F1* and *MYC*, which are associated with fibroblast core serum response^[1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!